Promotes transparency and accountability in the use of artificial intelligence by health insurers to manage coverage and claims.
Impact
The proposed legislation has far-reaching implications for current practices in the health insurance sector. By mandating that insurers disclose their use of AI, including the decision-making processes and the types of AI models applied, the bill addresses current concerns regarding the opaque nature of automated decision computations. This change is expected to enhance compliance with both state and federal regulations regarding management of healthcare claims and coverage, leveraged through rigorous reporting requirements set forth by relevant state authorities.
Summary
Bill S2010, officially titled 'The Transparency and Accountability in Artificial Intelligence Use by Health Insurers to Manage Coverage and Claims Act', seeks to regulate the implementation of artificial intelligence (AI) by health insurers in Rhode Island. Its primary focus is to ensure that health insurers maintain transparency and accountability when using AI in decision-making processes related to healthcare coverage and claims management. By promoting oversight on how AI impacts healthcare decisions, the bill aims to safeguard the interests of policyholders and ensure adherence to regulatory standards.
Contention
While supporters argue that S2010 will protect consumers by creating clearer guidelines for AI usage, critics may raise concerns about the potential for increased bureaucratic oversight that could stifle innovation within insurers. There are fears that stringent regulations could elevate operational costs for insurers, indirectly leading to higher premiums for policyholders. Additionally, stakeholders may debate whether this bill adequately addresses the complexities of patient care and operational flexibility needed in the fast-evolving landscape of healthcare technology.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
Requires DOA provide inventory of all state agencies using artificial intelligence (AI); establishes a 13 member permanent commission to monitor the use of AI in state government and makes recommendations for state government policy and other decisions.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Drains: appeals; period to appeal apportionment or assessment costs on drain projects; modify. Amends secs. 72 & 72a of 1956 PA 40 (MCL 280.72 & 280.72a).